RxDoctor Payments Data

Monika Bartoli

Family · McDonough, GANPI 1174174171

Payments from drug & device makers

$2,315in general payments, 2019–2025

Across 89 payments — averaging $26.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biohaven Pharmaceuticals, Inc.$1K
  • GSK$167
  • Lilly USA, LLC$148
  • Otsuka America Pharmaceutical, Inc.$132
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$129
  • Novo Nordisk$104
  • plus $547 from 14 others

What the payments were for

  • Consulting fees$80035%
  • Travel & lodging$492%
  • Food & beverage$1,46663%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,315 in reported general payments places this provider in the 80th percentile of 6,258 family providers in Georgia.

See all family providers in Georgia

Medicare billing

Part B allowed, 2024
$84,454
Medicare patients
211
Services billed
2,816

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide44$92,156
MounjaroTirzepatide49$70,995
JardianceEmpagliflozin47$54,120
TrulicityDulaglutide27$52,877
FarxigaDapagliflozin Propanediol42$40,330
Trelegy ElliptaFluticasone/Umeclidin/Vilanter20$23,538
JanuviaSitagliptin Phosphate23$23,381
EliquisApixaban21$21,503
MyrbetriqMirabegron13$14,405
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog13$6,605
SymbicortBudesonide/Formoterol Fumarate11$6,141
Albuterol Sulfate HfaAlbuterol Sulfate101$2,583
Wixela InhubFluticasone Propion/Salmeterol11$2,512
Gabapentin109$1,967
Atorvastatin Calcium253$1,854

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$148$123,87276 claims
Novo NordiskOzempic$104$92,15644 claims
Boehringer IngelheimJardiance$34$54,12047 claims
AstraZenecaFarxiga, Symbicort$103$46,47253 claims
GSKTrelegy Ellipta$167$23,53820 claims
MerckJanuvia$35$23,38123 claims
PfizerEliquis$34$21,50321 claims
AbbVieSynthroid$42$1,00218 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 6,258 family providers in Georgia.

Other family in McDonough

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →